A new National Bureau of Economic Research working paper reported little evidence that GLP-1 use among adults with diabetes produced measurable changes in mental health, self-rated health, employment, or marital status. The authors are University of Chicago Harris School of Public Policy economist Robert Kaestner and coauthor Cuiping Schiman.

GLP-1 medications such as Ozempic have reshaped treatment for Type 2 diabetes, helping patients manage blood sugar, lower cardiovascular risk and, in many cases, lose a substantial amount of weight. The open question was whether those physical gains spill over into the rest of a person's life, and this is the paper that went looking.

Why the question matters now

Insurers and government programs are weighing whether to broaden access, and the medical case is already well documented. What is not documented is whether the drugs deliver social or economic gains that would strengthen the coverage argument, which is exactly the gap Kaestner says had not been examined.

"We know these drugs improve health outcomes, and there's been a great deal of research documenting those benefits," Kaestner said. "What hadn't really been examined was whether those improvements extended into other parts of people's lives."

How they did it

The pair used more than 10 years of data from the nationally representative Medical Expenditure Panel Survey, focusing on adults with diabetes between 2012 and 2023. Rather than only comparing users with non-users, they followed the same individuals over time to see whether circumstances changed after treatment started.

That design choice is the most interesting thing in the paper. GLP-1 users initially looked different from non-users on employment and marriage, but those differences mostly disappeared once the researchers tracked change within the same people, suggesting the original gaps reflected who takes these drugs rather than what the drugs did.

Limitations

Results were similar at roughly one year of use and over a two-year follow-up, and in both cases the measured life outcomes barely moved. Kaestner emphasized this does not prove the drugs have no effects outside physical health, since some changes may be too subtle for the measures used.

"Those are important measures, but they don't necessarily capture changes in self-esteem, relationship quality, or other day-to-day experiences," he said. The researchers also stressed the findings do not call the medical value of the medications into question.

Bottom line

For adults with diabetes, Kaestner said the clearest measurable benefits remain the ones clinical research already established: improved glycemic control, weight loss and better physical health. As use grows beyond diabetes, he said, this remains a very new area of research, with more chances to test whether broader effects show up in other groups or over longer periods.